Follow Us 
For more information contact the Clinical Trials department at 386.254.4213
|
Protocol ID Click on ID for more information Updated 1/16/12 |
Breast |
|
|
Adjuvant RT
Must be randomized prior to start of any treatment |
A Randomized PhaseIIIStudy of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for
Closed to enrollment for: DCIS patients > 50 and node negative patients >50 Click here for Consent |
|
|
Adjuvant HER-2 positive Ductal in situ |
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER-2 Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Click here for Her 2 Testing Consent Click here for Registration Consent |
|
|
Adjuvant node positive or high-risk node negative |
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six cycles of Docetaxel Plus Cyclophosphamide or four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-risk Node-Negative HER2-Low Invasive Breast Cancer Click here for Consent |
|
|
Neoadjuvant HER2 Positive |
Randomized Phase III Trial Of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab As Neoadjuvant Treatment Of HER2- Positive Primary Breast Cancer Click here for Consent |
|
|
|
|
|
|
1-3 Positive Nodes Hormone Receptor positive/ HER2 negative |
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Click here for step 1 consent Click here for step 2 consent |
|
|
Newly Diagnosed Breast Cancer with and intact Primary tumor with 1 or more sites of breast cancer.
Prior H/O non invasive Breast Cancer allowed |
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Click here for consent |
|
|
|
GI - Colon |
|
Post-op Adjuvant colon |
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage IIIColon Click here for consent
|
|
|
Lung |
|
Post-op adjuvant NSCLC |
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4CM)-IIIA Non-Small Cell Lung Cancer (NSCLC)
Click here for consent |
|
Stage IV NSCLC newly diagnosed or recurrent after previous surgery and/or RT
|
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Click here for consent |
|
Newly diagnosed Stage IV non-squamous NSCLC |
A Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer of Nonsquamous Histology
Click here for consent |
|
Supportive Care For Advanced NSCLC |
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500µg Once-Every-3-Weeks in Anemic Subjects with Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy Click here for consent |
|
|
Supportive Care Breast or Gynecologic |
|
History breast or gynecologic cancer No evidence disease Post menopausal Vaginal symptoms present ≥ 2 months prior to randomization . |
Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Click here for consent |
